Volume | 5,866,568 |
|
|||||
News | - | ||||||
Day High | 2.02 | Low High |
|||||
Day Low | 1.65 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Lexicon Pharmaceuticals Inc | LXRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.66 | 1.65 | 2.02 | 1.74 | 1.70 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
14,495 | 5,866,568 | $ 1.81 | $ 10,626,316 | - | 0.92 - 3.789 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:55:30 | 10 | $ 1.76 | USD |
Lexicon Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
423.72M | 244.92M | - | 1.2M | -177.12M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Lexicon Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.55 | 2.02 | 1.48 | 1.63 | 3,752,044 | 0.20 | 12.90% |
1 Month | 2.04 | 2.1682 | 1.48 | 1.72 | 3,058,719 | -0.29 | -14.22% |
3 Months | 2.35 | 3.73 | 1.48 | 2.43 | 4,630,515 | -0.60 | -25.53% |
6 Months | 1.38 | 3.73 | 0.92 | 2.04 | 3,700,926 | 0.37 | 26.81% |
1 Year | 2.49 | 3.789 | 0.92 | 2.04 | 3,041,953 | -0.74 | -29.72% |
3 Years | 4.91 | 6.3299 | 0.92 | 2.45 | 1,528,812 | -3.16 | -64.36% |
5 Years | 6.08 | 9.65 | 0.92 | 3.21 | 1,924,444 | -4.33 | -71.22% |
Lexicon Pharmaceuticals Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. |